IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Rhea-AI Summary
IN8bio (NASDAQ:INAB) reported updated data from its INB-200 Phase 1 and INB-400 Phase 2 studies of repeat-dose DeltEx DRI in newly diagnosed glioblastoma at ASCO 2026.
Median progression-free survival reached 13.0 months and median overall survival currently exceeds 19.5 months, versus 6.6 and 13.2 months for standard-of-care alone, with 43% vs 20% 24‑month survival and a generally well-tolerated safety profile.
AI-generated analysis. Not financial advice.
Positive
- mPFS 13.0 months vs 6.6 months with standard-of-care
- mOS exceeds 19.5 months vs 13.2 months with standard-of-care
- 24‑month survival 43% vs 20% for standard-of-care patients
- No dose-limiting toxicities, CRS, or neurotoxicity reported
- Cold-to-hot tumor microenvironment shift with broader T cell infiltration
- Higher γδ T cell and CD4+ levels correlated with overall survival
Negative
- Results based on 17 newly diagnosed glioblastoma patients treated
- Median overall survival in repeat-dose cohort not yet reached
- Data are early-phase from Phase 1 and Phase 2 studies
Key Figures
Market Reality Check
Peers on Argus
INAB gained 3.89% while momentum peers APRE and PCSA appeared in scanners with gains of about 7.37% and 7.42%. Scanner data flags this as stock‑specific rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 07 | Q1 2026 earnings | Positive | -1.3% | Reported GBM mPFS 13.0 vs 6.6 months SOC and cash of $21.9M. |
| May 06 | Conference previews | Positive | -2.5% | Announced upcoming γδ T cell data at ASCO and other 2026 meetings. |
| Apr 03 | Inducement grants | Neutral | -2.1% | Granted stock options for 11,800 shares to new employees. |
| Mar 12 | FY 2025 earnings | Positive | -1.1% | Highlighted durable GBM survival data and extended cash runway into H1 2027. |
| Feb 24 | Conference appearance | Neutral | +2.6% | Announced presentation and meetings at TD Cowen health care conference. |
INAB has often traded lower after positive GBM and earnings updates, suggesting a pattern of selling into good news.
Over the last few months, INAB has repeatedly highlighted DeltEx DRI GBM data with mPFS of 13.0 months vs. 6.6 months SOC and improving mOS, alongside strengthening its balance sheet via a private placement and reporting cash of $27.1M at year-end 2025 and $21.9M at Q1 2026. Despite clinically positive messages, shares often drifted lower after earnings and data‑focused releases. Today's ASCO update extends this GBM survival story with more mature mOS >19.5 months, fitting into an ongoing clinical narrative rather than a new program shift.
Regulatory & Risk Context
An effective Form S-3/A shelf filed on May 18, 2026 permits IN8bio to offer up to $200,000,000 of various securities, enabling flexible capital raises via supplements like the $2,800,000 ATM registered on June 1, 2026.
Market Pulse Summary
This announcement highlights updated ASCO 2026 data for DeltEx DRI in newly diagnosed glioblastoma, with mPFS of 13.0 months and mOS exceeding 19.5 months versus SOC benchmarks of 6.6 and 13.2 months. The dataset remains small at 17 patients but shows encouraging survival and immunologic signals. Historically, INAB has repeatedly emphasized this GBM program and strengthened its financing tools, including a $200M shelf and a $2.8M ATM, making future clinical maturation and funding decisions key watchpoints.
Key Terms
median progression-free survival medical
median overall survival medical
gamma-delta (γδ) t cell medical
cytokine release syndrome medical
tumor microenvironment medical
standard-of-care medical
phase 2 medical
AI-generated analysis. Not financial advice.
Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).
Results demonstrate the potential for meaningful improvement in outcomes with gamma-delta T cell therapy in combination with the standard-of-care that has remained unchanged for over 20 years.
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ T cell engagers (TCEs) for cancer and autoimmune diseases, today announced updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 studies at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Among patients who received up to six repeat doses of genetically modified gamma delta (γδ) T cells (DeltEx DRI), median progression-free survival (mPFS) reached 13.0 months, nearly double the 6.6 months observed in patients receiving standard-of-care (SOC) alone. mOS has not yet been reached in repeat-dose patients and currently exceeds 19.5 months (+
“These data continue to support the potential of DeltEx DRI to change the treatment landscape for newly diagnosed glioblastoma,” said William Ho, Chief Executive Officer and co-founder of IN8bio. “Patients today face the same outcomes as patients diagnosed over twenty years ago. Despite more than two decades with little advancement, we are seeing encouraging signals of durable disease control and prolonged survival supported by observed biomarker and immune reconstitution data. The need for new treatments for this devastating cancer is critical.”
Glioblastoma (GBM) is among the deadliest cancers. Despite the SOC combination of surgery, radiation, and temozolomide (TMZ) chemotherapy, known as the Stupp regimen, mOS has remained at only ~14.6 months since 2005. The data presented at ASCO included findings from 17 treated patients with newly diagnosed GBM receiving IN8bio’s DeltEx DRI γδ T cell therapy in combination with SOC, along with a comparison to contemporaneously enrolled patients receiving only the SOC.
The studies demonstrated that intracranially delivered DeltEx DRI was generally well tolerated, with no dose-limiting toxicities, cytokine release syndrome (CRS), or neurotoxicity events reported.
Additional translational analyses integrating histopathology with artificial intelligence (AI) technology demonstrated that DeltEx DRI treatment drove a cold-to-hot tumor microenvironment shift, with broad T cell infiltration and reduction in immunosuppressive granulocytes not observed in SOC patients. Repeat DeltEx DRI dosing resulting in higher total doses also increased cumulative γδ T cell and CD4+ levels that correlated significantly with overall survival, linking sustained immune reconstitution to improved outcomes in a dose-dependent manner. Taken together these data point to a γδ T cell-mediated local mechanism with systemic reach.
“These findings suggest DeltEx DRI may not only directly target residual tumor cells, but also help sustain immune competency during chemotherapy treatment,” said Kate Rochlin Ph.D., President and Chief Operating Officer of IN8bio. “The ability to preserve and restore key immune cell populations while driving local tumor microenvironment remodeling represents an important potential advancement in GBM immunotherapy.”
About INB-200 and INB-400
INB-200 and INB-400 are clinical-stage programs evaluating DeltEx DRI, IN8bio’s genetically modified gamma-delta T cell platform designed to resist the lymphodepleting effects of temozolomide chemotherapy. The therapy is intended to allow gamma-delta T cells to remain active during chemotherapy administration and target stress-induced ligands expressed on glioblastoma cells.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.
Investors & Company Contacts:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
